T regulatory cells (Tregs) play a vital role in suppressing heightened immune response, and thereby promote a state of immunological tolerance. Tregs modulate both innate and adaptive immunity, which makes them potential candidates for cell-based immunotherapy in the suppression of uncontrolled activation of graft-specific inflammatory cells and toxic mediators. Graft-specific inflammatory cells (T effector cells) and other inflammatory mediators (immunoglobulins, active complement mediators) are mainly responsible for graft vascular deterioration followed by acute/chronic rejection. Treg-mediated immunotherapy is under investigation to induce allospecific tolerance in various ongoing clinical trials in organ transplant recipients. Treg immunotherapy shows promising results; however, key issues regarding Treg immunotherapy remain unresolved, including the mechanism of action and specific Treg cell phenotypes responsible for a state of tolerance. This review highlights the involvement of various subsets of Tregs during immune suppression, the novelty of Treg functions, effects on angiogenesis, emerging technologies for effective Treg expansion, and plasticity and safety associated with clinical applications. Altogether, this information will assist in designing single/combined Treg-mediated therapies for successful clinical trials in solid organ transplantations.
host tissue destruction (7-9) ( Figure 1A T cells) (13) and, finally, dendritic cellspecific intercellular adhesion molecule-3-grabbing non-integrin cells (DC-SIGN + macrophages) (14) .
Treg Subsets
Tregs, produced from naïve CD4 + T cells in the thymus as functionally mature CD4 + T cell subsets, play a vital role in providing immunological tolerance to self-antigens (15, 16) . The regulatory cells neutralize killer T cells during inflammation (17) and suppress heightened immune responses destructive to host tissue in organ transplant recipients (18) (19) (20) .
defends the host from a broad range of pathogens and foreign tissue antigens while preventing unwarranted and exaggerated immune reactions that would be deleterious to the host tissue (2) (3) (4) .
During an immune response, T and B cells modulate an effective response against foreign tissue antigens, characterized by broad antigen recognition, high specificity, strong effector response and long-term immunologic memory (5, 6 ). An effective immune response balances unresponsiveness to self-antigens (immunological self-tolerance) and the magnitude of adaptive immune responses to non-self-antigens, thereby preventing InTRODUCTIOn A typical immune response requires a firm balance between activation and attenuation, dependent upon the balance of T effector and regulatory T cell function, in turn dependent on molecular signaling. Alterations in the cell transcriptional phase are critical to the onset of immune self-tolerance (1) . Likewise, immunotherapies for organ transplantation face challenges in achieving enough immunosuppression to prevent organ rejection while limiting autoreactivity, without impairing the host's ability to guard against opportunistic infections and malignancies. The immune system Tregs (5-10% CD4 + T cells) are crucial to the regulation of self-tolerance and are capable of inhibiting antigen-specific inflammatory responses (7, (21) (22) (23) (24) ( Figure 1B ). Regulatory T cells, originally identified as antigen-specific T suppressor cells, uniquely express surface CD25 and the nuclear FOXP3 gene (25, 26) . The FOXP3 gene is required for immunosuppressive functions and regulation, acting through suppression of cytokines interleukin-2 (IL-2), interferon gamma (IFN-γ) and interleukin-4 (IL-4), and activation of interleukin-10 (IL-10), high-affinity IL-2R, CD25, cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and glucocorticoidinduced TNFR-related protein familyrelated genes/proteins (20, 21, (26) (27) (28) (29) and local consumption of growth factors (8, 58) . Cell-cell interactions of Tregs  and dendritic cells trigger the release of  IFN-γ, a key inducer of indole amine 2, 3 dioxygenase, which catalyzes the conversion of tryptophan to kynurenine (63) . In turn, release of kynurenine triggers generation of T regulatory cells (64, 65) . During the process of immune inflammation, Tregs release a myriad of molecular mediators, which include several cytokines (TGF-β1, IL-35, IL-10), the cytotoxic molecule perforin and granzymes, to mitigate immunosuppressive T cells and control inflammation (45, 66) (Figure 2 ). TGF-β1 is one of the key mediators, performing both offensive (67) and defensive (68, 69) functions of Tregs during immunosuppression. Tregs utilize TGF-β1 to suppress T cell activation and differentiation to dampen inflammatory response (70) . In addition, TGF-β1 released from Tregs has the potential not only to convert naive T cells into iTregs and Th17 to assist in their fight against local inflammatory condition, and defend Tregs against apoptosis and destabilization during inflammatory phase (68, 69) , but also to affect the activity of cytotoxic T cells and APCs (71) (Figure 2 ). During a regulatory response, TGF-β1 plays a key role in inflammation, T cell lineage, antibody production, immunosuppression and maintenance of tolerance (70) . TGF-β1 is also critical to the development and differentiation of FOXP3 + Tregs (72) (73) (74) . In addition, TGF-β1 is essential for the generation of IL-17-producing Th17 cells (70) , and recent findings indicate that TGF-β1 is involved in the generation of IL-9-producing Th9 cells (75) . These observations highlight the role of TGF-β1 in T cell proliferation and differentiation (75 (56) . Under antigen-stimulated in vitro conditions, Tregs suppress the proliferation and cytokine production of effector T cells irrespective of antigen specificity (56) . Tregs also play specialized regulatory functions during inflammatory conditions and are key regulators in switching off the immune response after the onset of the inflammatory phase (18) . Under normal circumstances nTregs prevent autoimmune diseases while iTregs actively modulate transplantation tolerance (9, 57) . In vivo and in vitro Tregs are characterized by an anergic state with suppressive functions and are able to inhibit multiple stages of target cell activities (7, 16) . nTregs have the potential to suppress proliferation and differentiation of naïve T (CD4 + and CD8 + ) cells into effector T cells, and also suppress effector activities, differentiation and functions of NK cells, NK T cells, B cells, macrophages, osteoclasts and DCs (5, 20, 58) . As reported in preclinical and clinical studies, immune modulation through Treg regulation is a decisive factor in allografts due to the insufficient number of Tregs, which favor allograft injury and rejection in organ transplantations (59) (60) (61) (62) . Various modes of Tregmediated suppression have been proposed demonstrating that Tregs adopt various mechanisms for immunosuppression, including cell-contact-dependent secretion of immunosuppressive cytokines cells and release of IL-10, IL-17 and IFN-γ (36, 37) .
iTregs. iTregs are generated in the periphery and express CD4 FOXP3 as surface markers. They act through IL-10 and TGF-β (38) (39) (40) .
Tr1 Cells. Tr1 cells, which display CD4 and CD25, are generated from non-Treg cell precursors and draining lymph nodes. They suppress effector Th cell migration and function and suppress mast cells, basophils and eosinophils through the release of IL-10 (41 
Treg-Mediated Immunosuppression
Treg activation is antigen-specific, which suggests that their immunosuppressive properties are a function of antigen exposure during an inflammatory response. In vitro experiments have shown that the suppressive property of Tregs requires T cell receptor (TCR)-mediated activation (45, 46) . In addition, antigen specificity modulates Treg proliferation and expansion in lymph nodes (47) . Immunotolerance is linked with donor-specific Treg proliferation and expansion, possibly through the protein, CTLA-4, membrane-bound TGF-β, LAG-3 and the cytolytic molecules Fas and granzyme B (76). However, constitutive expression of CD25 by Tregs gives them an initial competitive advantage for the consumption of IL-2 over naïve T cells, which express CD25 only after TCR stimulation (58) . As reported earlier, nTregs predominantly produce immunosuppressive IL-35, a new member of the IL-12 family, which confers a suppressive activity of Tregs (77) .
Tregs are also involved in growth factor consumption and cytokine deprivation, and thus favor target cell apoptosis. This phenomenon of Treg-mediated immunosuppression involves competitive consumption of IL-2. However, under in vitro conditions, Tregs can immunosuppress IL-2R-deficient T cells in the presence of exogenous IL-2. This favors target T cell proliferation in the presence of Tregs while endogenous target T cell production of IL-2 remains suppressed (58). Tregs reduction in microvascular and vessel growth (99, 100 
Tregs and angiogenesis
The process of angiogenesis in ischemic tissues is controlled by immune cells, which require Tregs and macrophages, with chemokines playing a key role in new vessel growth (92) . Tregs play a key role in suppressing excessive immune response during an inflammatory response, and also support vascular repair at different levels (93) . Loss of microvasculature may be an unappreciated root cause of chronic rejection for all solid-organ transplants (2, 94) . In clinical conditions, the ischemic phase favors the process of neovascularization (including vasculogenesis and angiogenesis) and characterizes the tissue microvascular repair and remodeling during allograft rejection (94) (95) (96) (97) . In addition to tissue-specific initial activators, neovascularization requires growth factors, chemokines and proteases that play distinct roles in promoting and refining tissue repair and regeneration. Most of the cellular machinery of the immune system plays a key role during the process of microvascular repair (98) . The involvement of T lymphocytes is also shown in microvascular and vessel development and, as reported, T cell-deficient nude mice exhibit a distinct have been characterized as displaying a wide range of immunosuppressive mediators, including TGF-β, CTLA-4, IL-10 and galectin-1, although it is still uncertain which mode of immunosuppression is the main mediator of immunoregulatory properties (78) . In addition, Tregs actively produce extracellular adenosine (ADP and AMP) and promote suppression of T effector cells through adenosine receptor signaling (79, 80) . CTLA-4 is a costimulation receptor and plays a crucial role in the development of T cell anergy. Some studies report that engagement of CTLA-4 with B7 on the APC leads to activation of the Treg (81), which further facilitates the release of several inhibitory cytokines such as IL-10 and TGF-β (82). Furthermore, proliferation of Tregs can be induced, leading to a positive feedback mechanism that ultimately results in the downregulation of T effector cell response in an antigenspecific manner (83) . Tregs can either inhibit effector activity of conventional T cells or downregulate APC function of target cells (58) . Additionally, Tregmediated immunosuppression can also operate through various mechanisms that involve not only cellular components but also unique proteins known as sirtuins (84) . These cellular and molecular signals require close spatial proximity between Tregs and effector T cells. Sirtuin 1 (Srt1) has antiinflammatory properties, and its therapeutic targeting may be a valuable factor in organ transplantation (84) (85) (86) (87) . Activated Treg cells show downregulated Sirt1, and this may be a key process in stabilizing FOXP3 expression and Treg phenotypes (86) , which may have clinical benefits in autoimmunity and transplantation (84, 85, 88 (Figure 3 ).
Treg-Mediated Immunotherapy in Transplants
Organ transplantation can be a life-saving procedure for patients with end-stage disease of the lung, heart, kidney or liver. Unfortunately, this treatment strategy is limited by chronic rejection of the transplanted organ, which occurs when the patient's immune system continually attacks and impairs the organ and ceases vascular flow required for graft survival (117, 118) . This process affects nearly all patients in the first 10 years following transplantation, and there is no effective therapy for this condition. Treg cell-based therapy can be achieved by administering Tregs cells to diseased patients (119 functional microvascular blood flow between donor and recipient grafts, which further facilitated allograft recovery from the severe hypoxia phase (112, 113) . In addition, supernatants of hypoxic Tregs were able to promote angiogenesis in vivo in cell-free Matrigel implants (114) . As reported in a left lung ischemia model, an increase in CD4 to transplant recipients (148) . However, the ratio of activated T cell subsets among CD4 + CD25 high T cells was augmented in stable liver and kidney transplant recipients as compared to healthy individuals (149) . The use of expanded Tregs and iTregs compared to nTregs requires more phenotypic evaluation for safety and quality control. CD127 is less useful after strong activation, for example, as it can downregulate on conventional T cells (150) . As discussed earlier, the plasticity and safety of expanded Tregs mainly depends on their state of FOXP3 expression (151) . The standard therapeutic intervention after transplantation should induce tolerance, and regulatory T cells play a pivotal role in maintaining homeostasis and self-tolerance through the modulation of immune effector functions (7, 16) . Treg cells can be found inside the tolerated graft, and these cells can have indirect allospecificity for donor antigens (151) . In patients transplanted with lung, liver or kidney grafts, a positive correlation between graft survival and the number of circulating Treg cells has been reported in both preclinical and clinical conditions (152) , and based on these observations, it is widely accepted that Tregs play a pivotal role in the induction of transplantation tolerance (153) (154) (155) . Therefore, this supports the possibility of using Tregs as a biological therapy to maintain tolerance to alloantigens. Preclinical research findings report that reconstitution of Tregs has been shown to ameliorate graft-versus-host disease and facilitate engraftment of the bone marrow (156) (157) (158) . Originally, natural Tregs had to maintain immunological selftolerance, but deficiency or dysfunction of these cells may lead to the onset of autoimmune disease (5). However, it was later realized that a decline in their number or function can also provoke tumor immunity (159) , whereas their antigenspecific subset expansion can potentiate transplantation tolerance (5) . Furthermore, Treg-mediated immunotolerance has been implicated in other pathological conditions including allergies, microbial infections and fetomaternal tolerance (120, 160, 161) , and in organ transplantation (52 (170), which contains a highly conserved CpG-rich region upstream of exon -1 and is referred to as the Treg cell-specific demethylated region (171) (172) (173) . This specific FOXP3 locus is fully demethylated in nTreg cells but remains methylated in iTreg cells and activated human conventional T cells that transiently express FOXP3 (164) . Tregs have been shown to display a unique feature that depends on their FOXP3 expression and the demethylation state of the conserved non-coding region 2/ Treg-specific demethylated region and Treg cell representative regions. researchers in testing the combinations of current drug-based therapies with Tregs, which will further minimize the side effects and thus morbidity caused by these toxic immunosuppressants (175) . Treg-based immunotherapy assures antigen-specific immunosuppression and cell dosage can be tightly controlled and affect long-lasting regulation in vivo, and can be individualized to each patient with very limited side effects (135) . Tregs possess unique defensive and offensive mechanisms, antigen specificity and promising therapeutic potential, as reported in both preclinical and clinical studies of solid organ transplantation, but these cells do not have sufficient efficacy as a stand-alone therapy to prevent chronic rejection in solid organ transplantation, and certain factors, including dose, specificity and plasticity, remain uncertain and challenging areas to uncover (176) . The future of Treg-based immunotherapy is dependent on effective clinical trials, technological advancements in Treg manufacture/expansion and better mechanistic understanding of Treg biology and transplantation tolerance in humans.
In summary, Treg-based immune control can be implemented as a potential pharmaceutical tool through an adoptive cell therapy protocol to rescue patients with inflammatory diseases, chronic inflammation and transplantation. This review highlights the clinical significance of Tregs and also emphasizes the difficulties encountered in transitioning from bench to bedside. Although Treg therapy is very effective and does not present side effects, various challenges, including different methods of Treg expansion, the cost of GMP-Treg manufacturing, safety, and difficulties with stability of the Treg phenotypes after adoptive transfer mean that its use as a standard therapy remains a challenge.
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COnCLUSIOnS
Recent research has highlighted the cellular and molecular basis of Treg development and function, and implicated dysregulation of Tregs in major immunological diseases, including allograft rejection (19, 23) . Tregs are instrumental in establishing immune tolerance and are important cellular mediators of cell-based therapy for clinical applications (135) . Efforts to unravel the complexity of Tregs are only just beginning, and further understanding of their biology and characterization of targets will undoubtedly enhance future therapeutic opportunities (10, 88, 134) . Increasing evidence indicates that Tregs could be used to inhibit pathogenic anti-transplant immunity (in the absence of immune suppression), but mechanisms to accomplish this goal are hampered by inadequate understanding, Treg expansion, cost of GMP Treg manufacturing, safety and difficulties with the stability of the Treg phenotype after adoptive transfer. The present and future therapeutic scope of Treg-based therapy will hopefully minimize the drug burden of immunosuppression on solid organ transplant patients. In coming years, Treg cell-based therapy will provide a novel therapeutic platform in transplantation as well as in other diseases. This will further assist both clinicians and
